U.S. Life Sciences Stock News

In February 2026, PT Pertamina (Persero) announced it had signed a memorandum of understanding with Halliburton to accelerate advanced well construction, hydraulic fracturing, acid stimulation, and digital drilling technologies in selected onshore fields across Indonesia. This collaboration highlights Halliburton’s push to pair unconventional completion expertise with closed-loop automation and artificial intelligence, deepening its role in technology-intensive international projects. Next,...

Pediatrix Medical Group (MD) has drawn investor attention after recent share performance, with the stock down about 7% over the past month and 17% over the past 3 months, despite positive 1 year and 3 year total returns. See our latest analysis for Pediatrix Medical Group. The recent 7% 1 month and 17% 3 month share price declines suggest fading near term momentum, even though the 1 year and 3 year total shareholder returns remain positive. This can reflect investors reassessing Pediatrix...

Houlihan Lokey filed an SEC prospectus supplement covering the resale of new Class A shares tied to recent acquisitions and performance milestones. The filing sets out how these newly issued shares can be resold by certain holders, clarifying the legal status of stock linked to completed deals. The move sheds light on how Houlihan Lokey structures equity based incentives for acquired teams and deal related performance. For you as an investor looking at NYSE:HLI, this filing provides an...

NIO (NYSE:NIO) has secured fresh equity investment into its intelligent-driving chip unit GeniTech (Shenji). The company is expanding its collaboration with Bosch to cover all three NIO brands, with a focus on smart EV and autonomous driving technologies. These recent moves are aimed at deepening NIO’s in house chip capabilities and broadening technology cooperation across its future vehicle lineup. NIO operates in the premium electric vehicle segment, with a focus on software defined cars,...

In February 2026, Western Midstream Partners reported fourth-quarter 2025 results that increased revenue to US$1,031.48 million but saw net income fall to US$187.18 million, while issuing 2026 guidance that includes adjusted EBITDA of US$2.5–2.7 billion and lower capital spending of US$850 million to US$1 billion. Alongside these results, the partnership raised its 2026 distribution guidance to at least US$3.70 per unit, including a planned quarterly increase to US$0.93 per unit starting...

Amentum Holdings (AMTM) has been attracting fresh attention after securing a contract to support the UK Ministry of Defence’s hypersonic weapons program, along with roughly US$1b in nuclear sector awards in FQ1 2026. See our latest analysis for Amentum Holdings. Amentum’s recent client wins in hypersonics and nuclear awards arrive after a mixed stretch for the stock, with a 16.5% 1 month share price decline but a 62% 1 year total shareholder return from today’s US$29.87 level. If this defence...

Belite Bio (BLTE) shares are under the spotlight after the company reported a fourth quarter net loss of US$25.32 million and a full year net loss of US$77.61 million, both above prior-year levels. See our latest analysis for Belite Bio. Despite the wider losses, Belite Bio’s share price has shown strong momentum, with a 26.16% 90 day share price return and a very large 1 year total shareholder return that sits near 5x. This may point to shifting expectations around its pipeline rather than...

Why S&P Global (SPGI) is on investors’ radar today S&P Global (SPGI) has drawn attention after recent trading left the stock with a mixed return profile, including negative moves over the past month and past 3 months despite longer term gains. See our latest analysis for S&P Global. At a share price of US$441.88, S&P Global has recently seen a 9.17% 7 day share price return after a weaker patch that included a 16.28% 30 day share price decline and a 15.86% 1 year total shareholder return...

Lucid Group (LCID) has come under fresh scrutiny after reporting a wider fourth quarter 2025 loss, workforce cuts of 12% in its U.S. salaried staff, and revised 2025 production figures. See our latest analysis for Lucid Group. The earnings miss, production revision and workforce cuts have coincided with a 1 year total shareholder return decline of 52.83% and a 3 year total shareholder return decline of 88.66%. The 90 day share price return decline of 22.36% suggests selling pressure has been...

In recent months, several law firms have filed securities class action lawsuits against Varonis Systems, alleging the company misled investors about its ability to convert customers to its SaaS platform and sustain ARR growth between February 4, 2025 and October 28, 2025. This legal pressure highlights a tension between the bullish long-term thesis on Varonis’ role in data-centric cybersecurity and fresh questions about the reliability of its past growth disclosures. We'll now examine how...

GeneDx Holdings (WGS) has just put fresh numbers on the table, reporting its full year 2025 results along with reaffirmed 2026 revenue guidance and an FDA Breakthrough Device designation for its key genomic tests. See our latest analysis for GeneDx Holdings. Despite strong 2025 results, reaffirmed 2026 revenue guidance and the FDA Breakthrough Device designation, GeneDx’s recent share price momentum has been weak, with a 30 day share price return of 17.19% and a 90 day share price return of...

Septerna stock: recent moves and what they might mean for investors Septerna (SEPN) has attracted attention after a month return of about 24% and a past 3 months return above 10%, prompting investors to reassess how its clinical-stage biotech profile aligns with this recent share performance. See our latest analysis for Septerna. The recent 24.3% 1 month share price return, alongside a 10.9% 3 month share price return and a very large 1 year total shareholder return, suggests momentum has...

What USA Compression Partners stock’s recent performance suggests USA Compression Partners (USAC) has drawn investor interest after a period where the unit price showed a 1 day decline of about 1%, set against positive returns over the past month and the past 3 months. See our latest analysis for USA Compression Partners. That small 1 day share price pullback sits against a 30 day share price return of 5.65% and a 90 day gain of 10.97%, while the 5 year total shareholder return of 212.85%...

Hagerty, Inc. recently reported its fourth-quarter and full-year 2025 results, with sales rising to US$221.42 million for the quarter and US$845.93 million for the year, and net income improving to US$6.92 million and US$41.46 million respectively. Alongside this stronger profitability, Hagerty issued 2026 guidance that includes lower reported revenue of about US$1.28–US$1.30 billion under a new Markel fronting arrangement and an expected net loss. Against this backdrop, we’ll now explore...

BridgeBio Pharma (BBIO) is back in focus after reporting Q4 and full year 2025 results, showing sharply higher revenue alongside continued net losses as investors weigh the impact of recent clinical and commercial progress. See our latest analysis for BridgeBio Pharma. Despite the recent Q4 earnings and a series of positive Phase 3 readouts, BridgeBio Pharma’s short term share price returns have softened, with a 30 day share price return of 14.0% and year to date share price return of 15.0%...

Why the latest earnings and guidance matter for NPK International NPK International (NPKI) issued full year 2026 revenue guidance of US$305 million to US$325 million alongside fourth quarter 2025 results, giving investors fresh data on both recent performance and management expectations. The quarter included US$75.2 million in sales, net income of US$14.6 million, and diluted earnings per share of US$0.17. The company also reported completion of a previously announced US$20.29 million share...

Recent inflation data came in hotter than expected, and renewed credit risk worries hit bank stocks broadly, including First Financial Bankshares (FFIN). Investors reassessed exposure to problem loans and economically sensitive lenders. See our latest analysis for First Financial Bankshares. The recent 7.5% one day share price decline and 7.2% 7 day share price return, on a last close of US$30.93, sits alongside a mildly positive year to date share price return of 3.03%. At the same time, the...

In February 2026, Hertz Global Holdings, Inc. reported fourth-quarter 2025 results showing sales of US$2,028 million, with quarterly and full-year net losses narrowing year on year despite lower annual sales of US$8,504 million. The company attributed its wider-than-expected fourth-quarter loss to more than US$100 million of external disruptions, while outlining operational changes and fleet refresh plans aimed at improving earnings quality. Next, we’ll examine how these externally driven...

Target (TGT) heads into a closely watched earnings report and investor meeting this week, just as it commits to selling only cereals without certified synthetic colors, a move that has triggered fresh scrutiny of the stock. See our latest analysis for Target. Those cereal changes land at a time when Target’s share price has climbed 25.78% over the past 90 days and 7.89% over the last 30 days, even as the 1 year total shareholder return is slightly negative and longer term total shareholder...

In late February 2026, Progyny completed a share repurchase of 6,530,363 shares for US$159.4 million and filed a US$93.26 million common stock shelf registration tied to an ESOP, shortly after reporting quarterly and full-year 2025 results that showed higher sales, net income, and earnings per share than a year earlier. Despite these milestones and record 2025 revenue and adjusted EBITDA, management’s cautious 2026 revenue guidance, adjusted for a large client transition, drew attention to...

Lineage (LINE) is back in focus after reporting fourth quarter and full year 2025 results, which included a swing to a Q4 profit and a sharply smaller annual net loss, catching investors’ attention. See our latest analysis for Lineage. At a share price of US$40.52, Lineage has seen a 5.8% 7 day share price return, a 13.5% 30 day share price return, and a 14.4% year to date share price return. However, its 1 year total shareholder return of a 29.3% decline shows that recent momentum is...

Why Qnity Electronics (Q) Is Back on Investors’ Radar Qnity Electronics (Q) has drawn fresh attention after reporting Q4 2025 results that topped analyst revenue and earnings expectations, rolling out a multi year productivity plan, and approving a US$500 million share repurchase program. See our latest analysis for Qnity Electronics. The strong Q4 surprise, fresh 2026 net sales guidance and new M&A ambitions have coincided with powerful momentum, with a 30 day share price return of 31.8% and...

Ryder System recently reported fourth-quarter 2025 results that exceeded expectations and paired them with an upbeat earnings outlook for 2026, highlighting resilient performance across its logistics and vehicle services operations. This strong update comes shortly after sizable insider share sales by senior executives, drawing attention to how leadership actions align with Ryder’s growth and capital allocation plans. With Ryder’s better-than-expected quarter and optimistic 2026 guidance now...

iRhythm Holdings (IRTC) has drawn fresh attention after recent share price moves, with the stock showing a 4.6% decline over the past day and a 13.4% slide over the past month. See our latest analysis for iRhythm Holdings. The recent 1 day share price return of 4.6% decline adds to a 30 day share price return of 13.4% decline and a year to date share price return of 23.7% decline. At the same time, the 1 year total shareholder return of 22.6% shows a very different long term picture,...